A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

NCT04875195 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin's Lymphoma
Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC